Citius Pharmaceuticals Inc (CTXR) — Cash Flow-to-Debt Ratio
Citius Pharmaceuticals Inc (CTXR) has a Cash Flow-to-Debt Ratio of -0.28x as of December 2025, meaning its operating cash flow of $-13.01 Million could theoretically repay 0% of its total liabilities ($46.92 Million) in one year. See Citius Pharmaceuticals Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Citius Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Citius Pharmaceuticals Inc across 15 annual periods. Also explore net asset growth rate of Citius Pharmaceuticals Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Citius Pharmaceuticals Inc (2011–2025)
Year-by-year debt coverage analysis for Citius Pharmaceuticals Inc. For market capitalisation and broader financial context, see market value of Citius Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.50x | $-26.55 Million | $53.41 Million | ▲ +25.0% |
| 2024 | -0.66x | $-28.20 Million | $42.55 Million | ▲ +72.2% |
| 2023 | -2.39x | $-29.06 Million | $12.18 Million | ▲ +11.1% |
| 2022 | -2.68x | $-28.36 Million | $10.57 Million | ▼ -6.7% |
| 2021 | -2.51x | $-24.25 Million | $9.65 Million | ▼ -50.0% |
| 2020 | -1.68x | $-16.93 Million | $10.10 Million | ▲ +37.9% |
| 2019 | -2.70x | $-12.44 Million | $4.61 Million | ▲ +24.0% |
| 2018 | -3.55x | $-11.32 Million | $3.18 Million | ▼ -10.1% |
| 2017 | -3.23x | $-7.97 Million | $2.47 Million | ▼ -183.6% |
| 2016 | -1.14x | $-5.90 Million | $5.18 Million | ▲ +34.3% |
| 2015 | -1.73x | $-2.39 Million | $1.38 Million | ▼ -465.1% |
| 2014 | -0.31x | $-705.05K | $2.30 Million | ▲ +78.1% |
| 2013 | -1.40x | $-20.60K | $14.69K | ▼ -217.2% |
| 2012 | -0.44x | $-20.32K | $45.98K | ▲ +48.8% |
| 2011 | -0.86x | $-20.78K | $24.05K | — |